CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tissue; injectable implants to promote breast tissue regeneration; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has a co-development agreement with 3D Systems Corporation for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
IPO Year:
Exchange: NASDAQ
Website: collplant.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/17/2023 | $22.75 | Buy | Alliance Global Partners |
New U.S.-based role to support growth strategy, partnerships, and scaling of rhCollagen product platforms REHOVOT, Israel, July 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced the appointment of Bowman Bagley as Vice President, Commercial North America. In this newly created role, Mr. Bagley will lead the company's commercial strategy and execution in North America, including sales and marketing, logistics, and expansion of market presence for CollPlant's rhCollagen-based products and platform
CollPlant's proprietary rhCollagen to be used in clinical and commercial applications REHOVOT, Israel, June 9, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics, today announced the expansion of its agreement with STEMCELL Technologies, a biotechnology company that develops and supplies specialized cell culture media, tools, and services to support research in stem cell biology, regenerative medicine, immunology, and related life sciences. The amended agreement broa
- Further protection granted in key territory applying to the significant and growing aesthetic and reconstructive markets - REHOVOT, Israel, June 4, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that the European Patent and Trademark Office has allowed a patent application related to CollPlant's injectable fillers and regenerative breast implant candidates, being developed for the aesthetic and reconstructive procedures markets, respectively.
REHOVOT, Israel, May 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,200,002 of the Company's ordinary shares at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered to purchase up to 1,200,002 of the Company's ordinary shares at an exercise pr
- In Q1 following a development achievement, CollPlant received a $2 million payment from AbbVie – - Advancement of regenerative breast implant program continues; encouraging findings continue to be observed - REHOVOT, Israel, May 28, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the first quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer commented, "While advancing our core programs, we've remained discip
REHOVOT, Israel, May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombina
CollPlant's novel rhCollagen BioInks are an available solution aligned with FDA's plan announced last week to phase out the animal testing requirement for the development of monoclonal antibody therapies and other drug candidates REHOVOT, Israel, April 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, commented today, following the United States Food and Drug Administration (FDA)'s groundbreaking step announced last week to advance public health by replacing animal testing i
CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corp
Conference call to be held on Wednesday, March 26, 2025 at 10:00 a.m. U.S. EST REHOVOT, Israel, March 19, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced that it will report financial results for the fourth quarter and full year of 2024 on Wednesday, March 26, 2025, before the opening of the U.S. financial markets. The Company will then host a conference call, the audio of which will be webcast to discuss its financial results and corporate updates on Wednesday, March 26th at 10:
REHOVOT, Israel, Feb. 24, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its distribution channels for its Vergenix™ STR product, in Europe and Asia. VergenixSTR is based on the Company's rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons including the elbow tendon (for treatment of "tennis elbow"), rotator cuffs, patellar tendons, the Achilles tendon, a
Alliance Global Partners initiated coverage of CollPlant with a rating of Buy and set a new price target of $22.75
HC Wainwright & Co. reiterated coverage of CollPlant Biotechnologies with a rating of Buy and set a new price target of $26.00 from $13.00 previously
6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
EFFECT - CollPlant Biotechnologies Ltd (0001631487) (Filer)
424B3 - CollPlant Biotechnologies Ltd (0001631487) (Filer)
F-1 - CollPlant Biotechnologies Ltd (0001631487) (Filer)
6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
D - CollPlant Biotechnologies Ltd (0001631487) (Filer)
424B5 - CollPlant Biotechnologies Ltd (0001631487) (Filer)
6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
REHOVOT, Israel, May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombina
CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corp
Conference call to be held on Wednesday, March 26, 2025 at 10:00 a.m. U.S. EST REHOVOT, Israel, March 19, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced that it will report financial results for the fourth quarter and full year of 2024 on Wednesday, March 26, 2025, before the opening of the U.S. financial markets. The Company will then host a conference call, the audio of which will be webcast to discuss its financial results and corporate updates on Wednesday, March 26th at 10:
-Promising results obtained from the pre-clinical study with CollPlant's commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and rapid ingrowth of native tissue -Innovative breast implant technology designed to address a $3.0 billion market opportunity -Cash and cash equivalents balance as of September 30, 2024 was $15.4 million -Conference call to be held today at 10:00 a.m. U.S. EDT – REHOVOT, Israel, Nov. 27, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration
- Conference call to be held on Wednesday, November 27, 2024 at 10:00 a.m. U.S. EST - REHOVOT, Israel, Nov. 12, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2024 on Wednesday, November 27, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on November 27th at 10:00 a.m. Eastern Standard Time. Confere
- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter
Conference call to be held on Tuesday, August 20, 2024, at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial statements for the second quarter of 2024 on Tuesday, August 20, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and webcast to discuss its financial statements and corporate updates on August 20 at 10:00 a.m. Eastern Daylight Time. Conference ca
Additional large-animal study with commercial-size breast implants commenced in December 2023 expected to conclude in June 2024 Cash and cash equivalents balance as of March 31, 2024, was $23.2 million Conference call and webcast to discuss its financial results and corporate updates on May 29 at 10:00 a.m. Eastern Daylight Time (details herein) REHOVOT, Israel, May 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced results for the first quarter ended 2024 and provided a corporat
- Conference call to be held on Wednesday, May 29, 2024 at 10:00 a.m. U.S. EDT - REHOVOT, Israel, May 16, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 29, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on May 29 at 10:00 a.m. Eastern Daylight Time. Conference call informat
Dermal filler program with AbbVie in clinical phaseRegenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4Ends 2023 with $26.7 million in cash and cash equivalentsConference call to be held on Thursday, April 4, 2024 at 10:00 a.m. U.S. EDT REHOVOT, Israel, April 4, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced financial results for the full year ended December 31, 2023 an
New U.S.-based role to support growth strategy, partnerships, and scaling of rhCollagen product platforms REHOVOT, Israel, July 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced the appointment of Bowman Bagley as Vice President, Commercial North America. In this newly created role, Mr. Bagley will lead the company's commercial strategy and execution in North America, including sales and marketing, logistics, and expansion of market presence for CollPlant's rhCollagen-based products and platform
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is
- Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov
REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced the appointment of Alisa Lask to its Board of Directors. Ms. Lask is based in the United States and has held leadership roles in medical aesthetics at both Galderma and Allergan. She will be the seventh independent member of the CollPlant Board. "Alisa brings a strong background in global strategy and marketing that will be very helpful to maximizing the v
REHOVOT, Israel, March 29, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced the appointment of Hugh Evans to its Board of Directors, increasing the board to six independent members. Continue Reading Mr. Hugh Evans U.S.-based Mr. Evans brings extensive board, 3D printing technology, and investment experience to CollPlant. He currently serves on the boards of four manufacturing technology companies including Factory Four, ZVerse, 3DM, and is also a Non-Executive Chairman of Culinary Printworks. He was formerly a board member of AquaVenture Holdings, which was acquired by Culligan International.
WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the
SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)
SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)
SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)
SC 13G - CollPlant Biotechnologies Ltd (0001631487) (Subject)
SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)
SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)
SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)
SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)
SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)
SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)